ArticleOncoimmunology

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Annika Nelde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.